Sign in Subscribe
Pharmaceutical industry

Merck & Co Faces Federal Probe and Credit Downgrade after Vioxx Withdrawal

Strategic Insights

— 1 min read

As a result of its voluntary withdrawal of Vioxx, a $2.5 billion-a-year arthritis and pain drug, pharmaceutical giant Merck & Co has found itself at the center of a major controversy. The company's decision to pull Vioxx from the market has led to a US federal Justice Department probe and a credit rating downgrade from Moody's. The investigation, which is being conducted under federal criminal statutes, has already resulted in a large number of lawsuits being filed against Merck.

Key Takeaways:

  • Merck & Co has been subpoenaed by the US Justice Department regarding the research and marketing of Vioxx, which could have a material adverse effect on the company's financial position and results of operations.
  • As of October 31, around 375 lawsuits had been filed against Merck by people claiming they were harmed by Vioxx, with around 1,000 plaintiffs involved.
  • Clinical trials have shown that after 18 months' treatment with Vioxx, the likelihood of cardiovascular events was increased.
  • Moody's has cut Merck's credit rating from AAA to AA2 due to the revenues that will be lost as a result of Vioxx's withdrawal from the market.
  • Standard & Poor's is reportedly reviewing Merck's triple-A rating, which could lead to further downgrades.
  • The Justice Department's investigation is being conducted under federal criminal statutes, indicating a potential for serious consequences for Merck.

Statistics:

  • $2.5 billion: The annual revenue generated by Vioxx before its withdrawal from the market.
  • 375: The number of lawsuits filed against Merck as of October 31, with around 1,000 plaintiffs involved.
  • 18 months: The duration of Vioxx treatment shown to increase the likelihood of cardiovascular events.
  • AAA to AA2: The credit rating downgrade of Merck by Moody's, indicating a potentially significant impact on the company's financial position.

Sources:

  • [1] Merck & Co. (2004). Quarterly filing with the US Securities and Exchange Commission.
  • [2] Marketletters. (No date). Passim, regarding Vioxx.
  • [3] Moody's. (No date). Credit rating downgrade of Merck & Co.

Read more